secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001493152-24-018161
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY
-----------------------------------------------------------------------

- R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.
- Initiated multi-dose cohort in Phase 1 trial of Decoy20 after positive preliminary results from second cohort.
- Granted key patent in January 2024 to expand intellectual property portfolio.
- Accepted for poster presentation at ASCO Annual Meeting on June 1, 2024, highlighting initial Phase 1 Decoy20 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/0001493152-24-018161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224018161/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer